All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process . Last year, about 9 million Medicare enrollees spent $3.4 billion out of pocket on the selected drugs from companies, including Johnson & Johnson (NYSE: JNJ ), Merck & Co Inc (NYSE: MRK ), Bristol Myers Squibb Co (NYSE: BMY ), and AstraZeneca Plc (NASDAQ: Full story available on Benzinga.com

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients’ T cells, which fight hostile cells within the body. Specifically, CAR T treatments work by reconfiguring T cells so that they attack proteins found on tumors. CAR T also attacks other cells altered by tumors. One reason this type of therapy is so promising is that it produces treatments that work well within each patients’ body. That’s because the treatments are specifically tailored to each patients’ T cells. This revolutionary techology has brought up some of the best cancer drug stocks we have ever seen. Moreover, unlike other cancer treatments, CAR T drugs enlist cells that come from the patients themselves in the cancer-fighting effort. In other words, CAR T produces treatments that are “personalized” to each patient. Finally, “ After a one-time infusion, the CAR T cells can continue to multiply in the patient’s body after being administered ,” Bristol-Myers Squibb (NYSE: BMY ) explained.

BMY faces a significant decline in sales due to loss of exclusivity for Revlimid, impacting stock valuations and lowering guidance for FY2023. Read here for more.

Bristol-Myers Squibb stock has hit a new low and is currently out of favor in the market. Check out why I''m bullish on BMY stock right now.

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BMY, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 10 uncommon options trades for Bristol-Myers Squibb. This isn''t normal. The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish. Out of all of the special options we uncovered, 5 are puts, for a total amount of $155,031, and 5 … Full story available on Benzinga.com

Bristol-Myers Squibb stock appears cheap with a low P/E ratio, but its sales are expected to decline due to patent expirations. Learn why I see BMY as grossly overvalued.

… during the period. Fortem Financial Group LLC’s holdings in … the last quarter. Catalyst Financial Partners LLC lifted its position … the first quarter. Catalyst Financial Partners LLC now owns 6 … Friday, September 15th. Truist Financial restated a “buy” rating …

Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2023 on Thursday, October 26, 2023. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com.

Although Bristol Myers Squibb is struggling to grow, its new product portfolio is promising. Click here to see why BMY stock is undervalued.

Bristol Myers Squibb''s defensive strategy to defend the value of its legacy products may not be successful. Check out why I''m neutral on BMY stock.